HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Tuesday, 7 May 2019

New HTA Report - Cabozanitinib and vandatinib for advanced or metastatic medullary thyroid cancer

Dr Paul Tappenden has lead on a new NIHR HTA Report - Cabozanitinib and vandatinib for advanced or metastatic medullary thyroid cancer

https://www.journalslibrary.nihr.ac.uk/programmes/hta/165119/#/

Image of NIHR HTA report
https://www.journalslibrary.nihr.ac.uk/programmes/hta/165119/#/

In addition, HEDS have contributed to the work on the STA: NICE Guidance.
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
https://www.nice.org.uk/guidance/TA556
Posted by at
Labels: , ,